Taken together, the phenotypic analysis of tumor-infiltrating leukocytes (TILs) might be important not only to evaluate the efficacy of immune therapy [25,26,27], but also to understand the mechanisms to overcome the acquisition of resistance to BRAF inhibitors [20,21,22,23]. The gene discussed is BRAF; the disease is neoplasm.